Esperanza Martín-Sánchez

9PUBLICATIONS
93CO-AUTHORS
Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Regenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 29, 2026
Immune biomarkers of increased infection risk in multiple myeloma.

Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V Kostopoulos

|Sep 23, 2024
A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies.

Aintzane Zabaleta, Laura Blanco, Peter S Kim

|Jul 10, 2024
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19.

Esperanza Martín-Sánchez, Luis-Esteban Tamariz-Amador, Camila Guerrero

|May 30, 2024
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.

Esperanza Martín-Sánchez, Laura Blanco, Peter S Kim

|Sep 08, 2022
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma.

Rosalinda Termini, David Žihala, Evangelos Terpos

|Dec 15, 2021
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies.

Luis-Esteban Tamariz-Amador, Anna Martina Battaglia, Catarina Maia

Pageof 2

Frequent Collaborators

6 joint publications

Jesús San-Miguel

5 joint publications

Bruno Paiva

4 joint publications

Luis-Esteban Tamariz-Amador

4 joint publications

Felipe Prosper